Top Stories
Top Stories
Biotech and Pharma

Pfizer's lung cancer drug gets FDA approval 

Key Points
  • Pfizer said its once-daily oral drug to treat a rare form of lung cancer received approval from the U.S. Food and Drug Administration.
  • The drug, Vizimpro, will look to treat previously untreated patients with a form of metastatic non-small cell lung cancer.
  • Pfizer said it now has 11 approved cancer treatments across 19 indications.
A man walks past Pfizer's world headquarters in New York.
Andrew Kelly | Reuters

Pfizer said on Thursday that its once-daily oral drug to treat a rare form of lung cancer received approval from the U.S. Food and Drug Administration.

The drug, Vizimpro, will look to treat previously untreated patients with a form of metastatic non-small cell lung cancer (NSCLC).

As the leading cause of cancer deaths, lung cancer represents the biggest opportunity for companies seeking to exploit the power of modern cancer therapies.

Pfizer said it now has 11 approved cancer treatments across 19 indications.

The study tested Vizimpro's efficiency and safety in 227 patients suffering from NSCLC. The company said 27 percent of the patients reported adverse events including cough, diarrhea and rashes.

Earlier this year, the FDA had granted the drug a priority review designation, which is given to medicines that may offer significant advances in treatment or may provide a treatment where no adequate therapy exists.

Next Article
Key Points
  • Eli Lilly said the U.S. Food and Drug Administration approved its migraine drug Emgality.
  • The move marked the third approval from a promising new class of treatments for the often debilitating headaches.
  • Lilly said it plans to sell the drug, known chemically as galcanezumab, at a list price of $6,900 a year, or $575 month.
  • That is identical to the list prices for the other new migraine treatments, Aimovig from Amgen and Novartis, and Teva Pharmaceutical's Ajovy.